A 22-year-old woman from Manchester has been told she has about 18 months to live after a lung cancer diagnosis she and doctors link to years of vaping. Kayley Boda began using reusable vapes at 15 and switched to disposable devices shortly before symptoms began. In January 2025 she started coughing up dark brown, grainy mucus and was turned away by clinicians eight times who diagnosed chest infections. After coughing blood in March 2025 she had a chest X-ray and, following seven biopsies, was told in August 2025 she had stage one lung cancer. Surgery in September 2025 to remove the lower lobe of her right lung upstaged the disease to stage three when six lymph nodes tested positive. She underwent chemotherapy and was given the all clear in February 2026, but a pleural effusion two months later revealed the cancer had returned in the lung lining. Boda is fundraising for a clinical trial in Germany and has urged others to stop vaping. Doctors say they cannot definitively prove the cause but that smoking and vaping would not have helped her condition.

President Donald Trump on April 16–17 nominated Dr. Erica Schwartz to lead the U.S. Centers for Disease Control and Prevention, naming three senior deputies alongside her: Sean Slovenski as deputy director and COO, Dr. Jennifer Shuford as deputy director and chief medical officer, and Dr. Sara Brenner as senior counselor for public health. Schwartz, a retired rear admiral in the U.S. Public Health Service Commissioned Corps and former deputy surgeon general in Trump’s first term, is a board‑certified preventive medicine physician with medical and public‑health credentials from Brown University and the Uniformed Services University and a law degree from the University of Maryland. The nomination must be approved by the Senate; NIH director Jay Bhattacharya is serving as acting CDC director during the likely months‑long confirmation process. The pick comes after a year of turmoil at the agency — including abrupt leadership changes, staffing and budget cuts, a shooting at CDC headquarters and controversy over vaccine policy under Health Secretary Robert F. Kennedy Jr. Many public‑health experts and CDC staff greeted the selection with guarded optimism, seeing Schwartz as a conventional, experienced choice but warning her authority could be constrained by political interference.

A University College London study using UK primary care data found patients starting gabapentinoids — gabapentin or pregabalin — faced a higher risk of hospitalised drug poisoning, particularly in the first month of treatment and when the drugs were combined with benzodiazepines or opioids. Researchers analysed prescriptions in the Clinical Practice Research Datalink Aurum from 2010–2020, focusing on 16,827 people who experienced at least one drug poisoning hospitalization drawn from about 1.35 million people prescribed gabapentinoids. Compared with non-treatment periods, risk rose in the first four weeks (adjusted incidence rate ratio, aIRR 1.81). Co-prescription risk was notably higher: benzodiazepines with gabapentinoids had an aIRR of 3.95 (fourfold increase) and opioids with gabapentinoids an aIRR of 2.14 (doubling) for the first four weeks. The study also found drug-poisoning risk was elevated in the 90 days before gabapentinoid initiation (aIRR 2.09). The authors, noting the self-controlled case-series design cannot eliminate all time-varying confounding, urged clinicians to monitor patients closely at treatment initiation and avoid or minimise concurrent opioid or benzodiazepine prescribing.

A team of about 50 researchers led by Paul Verweij at Radboud University Medical Center has warned of a "silent surge" in drug-resistant fungi in a Nature Medicine paper published April 2026. The researchers — from 16 organisations worldwide — say resistance is rising in pathogens including Candida auris, azole-resistant Aspergillus fumigatus and Trichophyton indotineae. They argue that resistance often originates in the environment, driven in part by widespread agricultural use of fungicides chemically related to medical azoles, and can spread long distances via airborne spores. People with weakened immunity, such as ICU patients, transplant recipients and cancer patients, face the greatest risk; Candida auris bloodstream infections can carry high mortality. The authors set out a five-step plan calling for increased awareness, strengthened surveillance, improved infection prevention and control, optimized antifungal use, and investments in diagnostics and new drugs. They urge the inclusion of antifungal resistance in the 2026 Global Action Plan on AMR and stress the need for coordinated One Health policies linking agriculture, environment and clinical practice.

A preprint analysis and Reuters report this week found that Eli Lilly’s tirzepatide, while producing larger average weight loss than Novo Nordisk’s semaglutide, was linked with greater losses of lean body mass. The Massachusetts data‑analytics firm nference analysed roughly 1,800 tirzepatide users and about 6,200 semaglutide users, finding tirzepatide associated with an average 1.1% greater lean mass loss at three months and about 2.0% more after 12 months. The preprint categorised a “depletive GLP‑1 metabotype” (>20% total weight loss and >5% lean mass loss) in 10.3% of tirzepatide patients versus 6.7% on semaglutide in the first year. Higher doses, longer treatment and baseline musculoskeletal pain correlated with greater lean mass decline for both drugs. Separately, U.S. prescription data for the week ending April 10 show Eli Lilly’s newly approved oral weight‑loss pill Foundayo had about 1,390 prescriptions versus more than 113,000 for Novo’s Wegovy pill in the same period. Market commentary and investor notes circulated April 16–17 highlighted potential competitive and access implications as the two companies press in the global GLP‑1 market.

Belgian biopharmaceutical group UCB said on April 17 it will acquire U.S.-based Neurona Therapeutics for $650 million upfront and up to $500 million in milestone payments, valuing the deal at as much as $1.15 billion. The acquisition, expected to close by the end of the second quarter of 2026, adds Neurona’s clinical-stage cell therapy NRTX-1001 — a pluripotent stem cell‑derived GABAergic interneuron therapy in Phase I/II trials for drug‑resistant mesial temporal lobe epilepsy — to UCB’s neurology portfolio. UCB said the transaction will not change its 2026 revenue guidance but expects adjusted EBITDA to grow in the high-single-digit to mid‑teens percentage range. Neurona’s backers include Fidelity and Schroders Capital; the startup previously raised significant private funding to advance its regenerative medicine programme. UCB described the move as a strategic expansion into advanced therapies aimed at durable, targeted repair of the nervous system for hard‑to‑treat seizure disorders.

New analyses and recent American Cancer Society reports show colorectal cancer deaths are rising among younger Americans and are concentrated among people with less formal education. ACS researchers, using government death records, examined more than 101,000 colorectal cancer deaths in people aged 25–49 from 1994–2023 and found the death rate in that group rose from about 3 to 4 per 100,000. Increases were almost entirely among those without a four‑year college degree: rates for people with only a high school diploma rose from roughly 4 to 5.2 per 100,000, while rates for those with at least a bachelor’s degree stayed near 2.7 per 100,000. Separate national death‑certificate analyses reported similar education gradients. Colorectal cancer has become the leading cancer killer for Americans under 50; incidence in younger adults has been climbing for years. Experts point to disparities in screening, later diagnosis, obesity, diet, physical inactivity and access to care as likely contributors. Researchers also caution that changes in how education is recorded on death certificates and lack of linked clinical data limit firm conclusions about causes.

About one in four U.S. adults — roughly 66 million people — reported using an artificial intelligence tool or chatbot for physical or mental health information or advice, according to a West Health–Gallup Center survey of more than 5,500 adults conducted Oct.–Dec. 2025 and released in mid-April 2026. Most users turn to AI for quick answers or additional information: 71% cited speed or extra research, 67% said they were curious, and many use AI before (59%) or after (56%) seeing a clinician. A substantial minority cited access and cost barriers: 42% wanted help outside normal hours, 27% did not want to pay for a doctor’s visit and 14% said they could not afford one. While 84% of recent AI health users still saw a provider, 14% reported not seeing a clinician they otherwise would have after receiving AI guidance — an estimated 14 million adults. Trust in AI health information is split roughly evenly: about one-third trust it, one-third neither trust nor distrust it and one-third distrust it; only 4% say they strongly trust AI accuracy, and roughly 11% reported encountering advice they judged unsafe.

The National Pharmacy Association (NPA) has warned patients to be wary of counterfeit weight‑loss injections being sold via cloned online pharmacies and social media, after a survey of 100 online pharmacies found around one in 10 had their websites or accounts copied by illicit sellers over the past year. Almost two in five respondents reported treating patients who had unknowingly bought fake weight‑loss drugs. The NPA, which represents about 6,000 pharmacies, said criminals have duplicated regulator logos and offered products at deeply discounted prices — one case involved counterfeit Mounjaro sold at about a quarter of the legitimate price. Pharmacies told the NPA that social media platforms and regulators’ responses have largely been insufficient, and the trade often involves no clinical consultation. The NPA has written to Health Secretary Wes Streeting seeking stronger safeguards, including proposals such as a dedicated pharmacy domain (eg. pharmacy.uk). The Medicines and Healthcare products Regulatory Agency (MHRA) said its criminal enforcement unit has made seizures and arrests and supported police raids on illicit manufacturing sites in Northampton and Sleaford earlier this year and will continue enforcement action.

An international consortium study published in April 2026 found that babies who were exclusively breastfed for at least three months carry distinct DNA methylation marks in blood years later. The Pregnancy and Childhood Epigenetics (PACE) Consortium analysed epigenetic data from 3,421 children across 11 studies in countries including Spain, the Netherlands, Finland, France, Greece, Lithuania, Germany, South Africa and the United States. DNA methylation differences were observed at genes linked to immunity and developmental processes in samples taken at ages 5–12 and were not present in cord blood, suggesting the changes arose after birth. The research was led by ISGlobal, the University of Exeter and the University of Bristol and published in Clinical Epigenetics, with funding from bodies including the UK Medical Research Council, Wellcome and Horizon 2020. The study did not assess whether the methylation differences produce functional changes in immunity or development, and authors emphasised the need for more diverse cohorts and further work to determine long-term health effects.

A Canadian Institute for Health Information (CIHI) report released April 16, 2026, shows hospital admissions for vaccine-preventable respiratory illnesses more than doubled in 2024–25 versus 2019, totalling about 57,700 cases (142 per 100,000 residents). COVID-19 accounted for over 40% of those admissions, while influenza and respiratory syncytial virus (RSV) together made up roughly 51%. Nearly half of admissions were in people aged 75 and older and about 20% were children under five. CIHI and the Public Health Agency of Canada flagged falling immunization coverage across at-risk groups — including drops in seasonal COVID and flu uptake — and created new indicators to track public-health capacity such as numbers of public-health nurses and inspectors. The report also highlights wide provincial and territorial variation, long average stays (about 23 days for COVID patients) and high per-admission costs (around CAD 28,500), and warns that strained hospital capacity and workforce shortages are compounding the burden on Canadian health systems.

A University of Warwick mental health researcher says waking repeatedly at about 3 a.m. is often driven by normal sleep-cycle dynamics combined with modifiable habits. Talar Moukhtarian, assistant professor at Warwick Medical School, explains that sleep proceeds in 90–110 minute cycles and that sleep becomes lighter toward the end of each cycle as cortisol begins rising ahead of morning. Brief awakenings are normal but can become prolonged when stress, rumination, late-day caffeine or alcohol, irregular schedules, screen exposure and an unsuitable bedroom environment intervene. Alcohol may help people fall asleep faster but fragments sleep later; caffeine can persist for up to six hours and lighten sleep. Moukhtarian recommends evidence-based sleep hygiene: keep a consistent wake time, limit late caffeine and alcohol, allow time to unwind, avoid night-time phone use and clock-checking, and get out of bed briefly to do something relaxing if unable to fall back asleep. She notes that persistent awakenings can feed a cycle of anxiety and insomnia and that cognitive behavioural therapy for insomnia (CBT‑I) is an effective treatment when problems continue. The guidance was published and republished across outlets on April 16, 2026.

April 16, 2026 — Roche said it will initiate a global, placebo-controlled Phase III study of Elevidys, the gene therapy for Duchenne muscular dystrophy (DMD), after feedback from the European Medicines Agency. The trial will enrol about 100 early ambulatory boys with confirmed DMD mutations and compare Elevidys to placebo over more than 72 weeks, with the primary endpoint the change in “time to rise” from the floor. Roche, which holds rights to Elevidys outside the United States, said the study is intended to generate the additional data needed for a European re-submission. Elevidys, developed by U.S. firm Sarepta Therapeutics and approved in nine countries, faced a negative EMA opinion last year after questions about clinical benefit and two patient deaths that prompted a temporary U.S. shipment pause and FDA restrictions. Roche cited long-term data and experience treating over 1,000 ambulatory boys. The move follows sales declines for Elevidys — roughly $900 million net product revenue in 2025 — and market setbacks that have reduced its earlier multi-billion-dollar forecasts.

Health officials and pediatric doctors warned on April 15-16, 2026 that rotavirus infections have risen across the United States since January, with wastewater surveillance and hospital reports indicating elevated community transmission, particularly in parts of the West and Midwest. The highly contagious virus causes vomiting, fever and severe watery diarrhoea that can lead to dehydration; there is no specific antiviral treatment and care is supportive, often requiring intravenous fluids. WastewaterScan — an academic program run with Stanford and Emory — reported high viral levels in sampled systems. Clinicians in Oklahoma City and other centres described increased admissions of infants and toddlers, many of whom were too young to be fully vaccinated, had not completed the vaccine series, or were unvaccinated. National vaccination coverage is reported at about 73.8% and has declined over the last eight years, raising concerns that lower uptake could fuel larger future surges. The Centers for Disease Control and Prevention and infectious disease experts are urging adherence to vaccination schedules, enhanced hygiene and monitoring to limit spread and severe outcomes among young children.

A Cochrane systematic review published in April 2026 analysed 17 randomized trials (2014–2024) involving 20,342 people with mild cognitive impairment or early dementia and concluded that monoclonal antibodies targeting amyloid‑beta produce little to no clinically meaningful improvement. Pooled results at about 18 months showed very small standardized mean differences on cognitive scales (eg, ADAS‑Cog SMD ≈ -0.11; CDR‑SB SMD ≈ -0.12). The review covered seven agents, including older failed programmes (bapineuzumab, crenezumab, gantenerumab, solanezumab), withdrawn aducanumab, and the more recent, approved drugs lecanemab and donanemab. It also found a higher incidence of amyloid‑related imaging abnormalities (ARIA) — brain swelling and microbleeds — though symptomatic ARIA was uncommon. The report prompted strong pushback from several prominent researchers and patient groups who criticised pooling heterogeneous drugs and trials, arguing newer antibodies have shown modest, meaningful effects. The findings have already been cited in coverage by major outlets and are feeding debates over clinical use, reimbursement and future research directions.

The U.S. Department of Health and Human Services has issued new guidance reshaping the Title X family planning program, signaling a shift away from contraception toward fertility awareness, pregnancy support and treatment of reproductive health conditions. The Office of Population Affairs said it expects to distribute about $257 million for up to 90 grant awards for a five‑year period, down from roughly $286 million in prior years; final funding will depend on enactment of the FY2027 budget. The guidance — issued in a detailed notice to prospective applicants — mentions contraception only once and encourages noninvasive, lifestyle‑focused approaches such as “fertility‑awareness‑based” methods and counseling to promote pregnancy. The administration’s FY2027 budget proposal also lists eliminating Title X as an option. The announcement comes as U.S. births fell to about 3.6 million in 2025 (a 1% decline from 2024) and the fertility rate dropped to 53.1 births per 1,000 women ages 15–44. Reproductive health groups including ACOG criticized the change as narrowing access to contraception and preventive care for low‑income patients; pro‑life and pronatalist groups have praised the pivot. Grant applications are due next January.

President Donald Trump on April 16 nominated Dr. Erica Schwartz, a former deputy surgeon general and retired Rear Admiral who served as the Coast Guard’s chief medical officer, to be director of the U.S. Centers for Disease Control and Prevention. The nomination, posted on the president’s Truth Social account, names three senior deputies alongside Schwartz: Sean Slovenski as deputy director and chief operating officer, Dr. Jennifer Shuford as deputy director and chief medical officer, and Dr. Sara Brenner as senior counselor for public health to HHS Secretary Robert F. Kennedy Jr. Schwartz, who holds an MD from Brown, an MPH and a law degree, would face Senate confirmation and is expected to inherit an agency beset by leadership turnover, staff departures, budget cuts and controversy over vaccine policy changes driven by the HHS secretary. The CDC has lacked a permanent director for much of Trump’s second term, with NIH director Jay Bhattacharya serving in an acting capacity. Reaction among public-health officials was mixed: some praised Schwartz’s credentials and experience; allies of Kennedy and vaccine-skeptical critics signaled concern.

The U.S. Food and Drug Administration has scheduled an expert advisory committee meeting for July 23-24, 2026 to consider whether licensed compounding pharmacies should be allowed to manufacture seven peptides that were placed on a restrictive list in 2023. The substances under review include BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon; a second session to evaluate five more peptides is planned before the end of February 2027. Regulators cited concerns in 2023 about immunogenicity, toxicity, impurity control and scant human safety data when the group was barred from compounding. The move follows public advocacy from Health and Human Services Secretary Robert F. Kennedy Jr., who has promoted broader access to peptides and said he has used them personally. Industry groups and some compounding pharmacies have welcomed the prospect of clearer regulatory pathways, while physicians, researchers and former FDA officials warn that expanding access without robust clinical trials could expose patients to unknown risks and encourage gray‑market suppliers. The agency has highlighted manufacturing and supply chain challenges, and the Pharmacy Compounding Advisory Committee currently has multiple vacancies that could affect deliberations.

Swedish researchers report that artificial intelligence trained on nationwide healthcare registry data can identify people at elevated risk of developing melanoma within five years. The study, led by Sam Polesie at the University of Gothenburg with major analysis by Martin Gillstedt, analysed records for 6,036,186 adults resident in Sweden between 2005 and 2014; 38,582 (0.64%) developed melanoma within five years. Models incorporating age, sex, diagnoses, medication history and socioeconomic variables distinguished future melanoma cases correctly in about 73% of instances, versus roughly 64% when using only age and sex. By combining clinical and sociodemographic inputs, the team identified small high‑risk subgroups with an estimated ~33% probability of developing melanoma within five years. The research, published in Acta Dermato‑Venereologica in April 2026, suggests selective, data‑driven screening could improve early detection and resource allocation. Authors and funders caution further validation, policy discussion and safeguards are needed before routine clinical deployment.

A BMJ Open study published in April 2026 found that five widely used AI chatbots frequently produce inaccurate or incomplete medical information. Researchers probed ChatGPT (OpenAI), Gemini (Google), Grok (xAI), Meta AI (Meta) and DeepSeek (High-Flyer) using 250 prompts across five topics — cancer, vaccines, stem cells, nutrition and athletic performance — designed to reflect common public queries and misinformation tropes. Overall, 50% of responses were judged problematic (30% somewhat problematic, 20% highly problematic). Open-ended prompts yielded disproportionately more highly problematic answers than closed questions. Model behaviour varied: Grok produced significantly more highly problematic responses while Gemini produced the fewest. Reference quality was poor (average completeness ~40%), with instances of fabricated citations; responses were typically expressed with unwarranted certainty and few caveats. Only two refusals to answer were recorded, both from Meta AI. The researchers noted limitations: the study stressed models with adversarial prompts, sampled five chatbots tested in February 2025, and commercial systems evolve rapidly, but concluded risks remain if chatbots are deployed for public-facing health guidance without stronger safeguards.